SMTI: Q2 2026 revenue grew 9% to $28.1M, with a 93% gross margin and a pending merger with MiMedx
Sanara MedTech Inc. (SMTI) reported Q2 2026 revenue up 9% to $28.1M, driven by soft tissue repair products, with gross margin at 93%. Adjusted EBITDA increased to $5.0M, but higher SG&A and interest contributed to a $0.4M net loss. The company also announced a pending merger with MiMedx Group and reorganized into a single surgical segment.
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations for revenue trajectory and margin quality, while also reassessing deal risk and potential future earnings power tied to the merger.
Market read
A combined quarterly performance update and merger announcement can drive repricing, but the lack of deal terms limits conviction.
What to watch
Merger impact is hard to price without disclosed consideration, expected synergies, regulatory path, and whether the financials reflect one-time items.
Background
The piece summarizes Sanara MedTech’s Q2 2026 results and notes it has announced a pending merger with MiMedx Group, consolidating operations into a single surgical-focused segment.
Ticker impact
Sanara MedTech reported Q2 2026 revenue up 9% to $28.1M with 93% gross margin and disclosed a pending merger with MiMedx.
Near-term volatility is likely as traders weigh improved top-line and gross margin against net loss and merger execution risk.
The article provides concrete quarterly financial metrics and confirms a merger announcement, but lacks deal terms, timing, and regulatory/financing details that would determine magnitude of repricing.
Market effects
Could modestly affect sentiment toward surgical repair medtech peers by highlighting margin resilience alongside consolidation activity.
No clear regional transmission described in the text.
Limited global relevance without deal size, geography, or regulatory milestones.
Counterpoint
High gross margin may not translate into sustainable profitability if SG&A and interest continue to drive net losses.
Key entities
- companySanara MedTech Inc.
Reported Q2 2026 revenue growth to $28.1M, 93% gross margin, adjusted EBITDA of $5.0M, and a net loss of $0.4M, alongside a pending merger with MiMedx.
- companyMiMedx Group
The counterparty in the announced pending merger with Sanara MedTech.
